Table 2.
Clinical Features | Cancer | Molecular Signatures | Reference |
---|---|---|---|
Prognosis | Head and neck squamous cell carcinoma | MRPL47 | (72) |
Neuroblastoma | MRPL11 | (73, 74) | |
Non-small cell lung cancer | MRPL15 | (75) | |
Lung adenocarcinoma | MRPL42 | (76) | |
Breast cancer | MRPL3 | (77) | |
MRPL13 | (78–81) | ||
MRPL12
MRPL13 |
(82) | ||
Gastric cancer | MRPS5 | (83) | |
MRPL35 | (84) | ||
MRPS29 | (85) | ||
MRPS17 | (86) | ||
Hepatocellular carcinoma | MRPL9 | (87) | |
MRPS12 | (88) | ||
Cholangiocarcinoma | MRPL27 | (89) | |
Colorectal cancer | MRPL52 | (90) | |
MRPL35 | (91) | ||
Ovarian cancer | MRPL15 | (92) | |
Adrenocortical carcinoma | MRPS23 | (93) | |
Metastasis | Breast cancer | MRPL52 | (94) |
MRPL15 | (95) | ||
Ovarian cancer | MRPL38 | (96) | |
Drug responsiveness | Muscle invasive bladder cancer | MRPL4 | (97) |